(2-氰基苯基)乙酸甲酯 | 20921-96-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (2-氰基苯基)乙酸甲酯
• 中文别名: 2-氰基苯乙酸甲酯；2-(2-氰基苯基)乙酸甲酯
• 英文名称: methyl 2-cyanophenylacetate
• 英文别名: methyl 2-(2-cyanophenyl)acetate
• CAS: 20921-96-4
• 化学式: C₁₀H₉NO₂
• mdl: MFCD02181139
• 分子量: 175.187
• InChiKey: MBLNSABLVSWAKD-UHFFFAOYSA-N

物化性质

• 沸点：
  273.8±15.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2926909090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  2-8℃

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl (2-cyanophenyl)acetate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl (2-cyanophenyl)acetate
CAS number: 20921-96-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H9NO2
Molecular weight: 175.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (2-氰基苯基)乙酸甲酯 在 4-二甲氨基吡啶 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 20.0h， 生成 吡仑帕奈
  参考文献：
  名称：

  一种吡仑帕奈的简便制备方法

  摘要：

  本发明涉及一种吡仑帕奈的简便制备方法。本发明方法包括(1)于溶剂中或无溶剂条件下，使式II化合物和式III化合物经酰胺化反应制备式IV化合物；(2)于溶剂中和催化剂存在下，使化合物IV与甲叉化试剂缩合得到化合物V，再在碱性试剂作用下脱氰化氢或氯化氢成环制备吡仑帕奈。本发明的方法原料价廉易得，工艺操作简便，所涉及单元反应选择性高，产品收率和纯度高，三废量少，反应原子经济性高，绿色环保。

  公开号：

  CN110028442B
• 作为产物：
  描述：

  2-氨基苯乙酸 生成 (2-氰基苯基)乙酸甲酯
  参考文献：
  名称：

  THE o-FORMYL- AND o-ACETYL-PHENYLACETIC ACIDS

  摘要：

  DOI：

  10.1021/jo01129a006

文献信息

• [EN] 1, 2 - DIHYDRO- 3H- PYRAZOLO [3, 4 - D] PYRIMIDIN -3 - ONE ANALOGS<br/>[FR] ANALOGUES DE 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE
  申请人：ZENO ROYALTIES & MILESTONES LLC

  公开号：WO2019028008A1

  公开（公告）日：2019-02-07

  Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.

  本文提供了式（I）的化合物。这些化合物以及其药学上可接受的盐和组合物对于治疗疾病或症状是有用的，包括那些以细胞过度增殖为特征的病症，比如乳腺癌。
• [EN] 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS<br/>[FR] DÉRIVÉS DE 1-HÉTÉROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE ET LEURS UTILISATIONS À TITRE DE MODULATEURS DE PDE9A
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009121919A1

  公开（公告）日：2009-10-08

  The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, Formula (I) with Hc is a mono-, bi- or tricyclic heterocyclyl group, the ring members of which are carbon atoms and at least 1, preferably 1, 2 or 3, heteroatom(s), which are selected from the group of nitrogen, oxygen and sulphur, which is in the form of -S(O)r - with r being 0, 1 or 2, and - said heterocyclyl group is or comprises 1 non-aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member and - said heterocyclyl group is bound to the scaffold by said 1 non- aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member. According to one aspect of the invention the new compounds are for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease.

  该发明涉及新型1,6-二取代吡唑吡嘧啶酮，化学式（I），其中Hc是一个单环、双环或三环杂环基团，其环成员为碳原子和至少1个，优选1个、2个或3个来自氮、氧和硫的杂原子，其以-S(O)r-的形式存在，其中r为0、1或2，所述杂环基团是或包括1个非芳香、饱和或部分不饱和的单环环，其中至少包含1个杂原子作为环成员，所述杂环基团通过所述至少包含1个杂原子作为环成员的非芳香、饱和或部分不饱和的单环环与支架相结合。根据该发明的一个方面，新化合物用于制造药物，特别是用于治疗感知、注意力、学习或记忆缺陷相关疾病的药物。新化合物还用于制造治疗阿尔茨海默病的药物。
• Synthesis, biological evaluation and molecular docking studies of novel 2-(2-cyanophenyl)-N-phenylacetamide derivatives
  作者：Lakshmi Narayana Sharma Konidena、Sathish Kumar Boda、Suresh Kumar Chettu、Kumaraswamy Sorra、Sreenivas Enaganti、Praveena Mukkavilli、N. S. Kameswara Rao、P. V. Anantha Lakshmi、Raghu Babu Korupolu

  DOI：10.1007/s11164-018-3434-9

  日期：2018.9

  series of novel 2-(2-cyanophenyl)- N -phenylacetamide derivatives 3(a-u) were designed and synthesized via selective amidation of methyl-2-(2-cyanophenyl)acetates over amidine formation by using AlMe3 as catalyst in good yields. All the newly synthesized derivatives were well characterized by 1H NMR, 13C NMR, FTIR and HRMS spectral techniques. All the synthesized title compounds were evaluated for their

  以AlMe 3为催化剂，设计并合成了一系列新颖的2-（2-氰基苯基） -N- 苯基乙酰胺衍生物 3（au） ，通过对2-（2-氰基苯基）乙酸甲酯进行a酰胺选择性酰胺化形成formation。。通过1 H NMR，13 C NMR，FTIR和HRMS光谱技术对所有新合成的衍生物进行了很好的表征。评价所有合成的标题化合物对三种癌细胞的体外抗癌活性。在所有化合物中， 3i （IC 50  = 1.20μM，IC 50  = 1.10μM）， 3j （IC 50  = 0.11μM，IC 50 = 0.18μM）， 3o （IC 50  = 0.98μM，IC 50  = 2.76μM）表现出优于标准依托泊苷（IC 50  = 2.11μM，IC 50  = 3.08μM）对MCF-7和A-549细胞系的抑制活性， 分别。所有化合物与 人类 拓扑异构酶II的对接分析 表明，化合物 3j 很好地适合了活性位点，显示出最佳对接分数158
• COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS
  申请人：Fuchs Klaus

  公开号：US20120115863A1

  公开（公告）日：2012-05-10

  The invention relates to novel cycloalkyl- or cycloalkenyl-substituted pyrazolopyrimidinones of formula (I), wherein Ā is selected from the group A 1 consisting of a C 3 -C 8 -cycloalkyl group or a C 4 -C 8 -cycloalkenyl group, whereby the members of C 3 -C 8 -cycloalkyl group being selected from the group of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl and cyclooctanyl; and the members of the C 4 -C 8 -cycloalkenyl group, being selected from cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclopentadienyl, cyclohexadienyl, cycloheptadienyl, cyclooctadienyl, cycloheptatrienyl, cyclooctathenyl, cyclooctatetraenyl. The new compounds shall be used for the manufacture of medicaments, in particular medicaments for improving perception, concentration, learning and/or memory in patients in need thereof. Chemically, the compounds are characterised as pyrazolopyrimidinones with a cycloalkyl-moiety directly bound to the 1 position of the pyrazolopyrimidinone and a second substituent in the 6 position which is bound via an optionally substituted methylene-bridge. Further aspects of the present invention refer to a process for the manufacture of the compounds and their use for producing medicaments.

  该发明涉及具有以下结构的新型环烷基或环烯基取代的吡唑吡咪啉酮化合物（I），其中Ā选自A1组中的C3-C8环烷基或C4-C8环烯基，其中C3-C8环烷基组成员选自环丙基、环丁基、环戊基、环己基、环庚基和环辛基；而C4-C8环烯基组成员选自环丁烯基、环戊烯基、环己烯基、环庚烯基、环辛烯基、环戊二烯基、环己二烯基、环庚二烯基、环辛二烯基、环庚三烯基、环辛烷基、环辛四烯基。这些新化合物可用于制造药物，特别是用于改善患者感知、注意力、学习和/或记忆的药物。从化学上讲，这些化合物被描述为在吡唑吡咪啉酮的1位上直接连接有环烷基基团，并且在6位上通过一个可选取代的亚甲基桥连接有第二取代基。该发明的进一步方面涉及一种制造这些化合物的方法以及它们用于生产药物的用途。
• 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用
  申请人：上海迪诺医药科技有限公司

  公开号：CN108623615B

  公开（公告）日：2022-12-13

  本发明涉及一种如式(I)所示的吡唑[3,4‑d]嘧啶‑3‑酮的大环衍生物和/或其药学上可接受的盐，以及含有如式(I)所示化合物的组合物和/或其药学上可接受的盐，制备方法和其作为Wee1抑制剂的用途及其作为癌症的化学疗法或放射性疗法的增敏剂中的用途；本发明的吡唑[3,4‑d]嘧啶‑3‑酮的大环衍生物可以有效的抑制Wee1及相关信号通路，具有良好的治疗和/或缓解癌症的作用。